Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Status:
Withdrawn
Trial end date:
2017-05-11
Target enrollment:
Participant gender:
Summary
Although a majority of children with leukemia and most hematological malignancies (Hodgkin's
and Non-Hodgkin's lymphomas) can be cured with conventional chemotherapy, a subset of
patients with resistant/recurrent high-risk disease are not cured with conventional treatment
regimens. Investigators hypothesize that HSCT from a partially matched donor can be safe and
effective for patients with very high risk hematologic malignancies when combined with
post-transplant cyclophosphamide for prevention of graft-vs-host disease (GVHD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago